Myriad Genetics COO withholds 2,055 shares for tax

Myriad Genetics Chief Operating Officer Mark Verratti reported a routine tax-related share withholding.

Accepted by SEC EDGAR 03/23/2026 - 04:22 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Myriad Genetics Chief Operating Officer Mark Verratti reported a routine tax-related share withholding. On March 22, 2026, 2,055 shares of Common Stock were disposed of at $4.58 per share to satisfy tax obligations tied to vesting restricted stock units. The number of shares withheld was based on the March 20, 2026 closing price. After this withholding, Verratti directly owns 630,715 shares of Myriad Genetics Common Stock.

Insider Trade Summary

Exercise Price or Tax Liability: 2,055 shares

Exercise Price or Tax Liability 1 txn

Insider Verratti Mark

Role Chief Operating Officer

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Stock	2,055	$4.58	$9K

Holdings After Transaction: Common Stock — 630,715 shares (Direct)

Footnotes (1)

1. F1. Represents shares of Common Stock withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units previously granted to the Reporting Person. The number of shares withheld was determined based on the closing price of Issuer's Common Stock on March 20, 2026.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Myriad Genetics (MYGN) report for Mark Verratti?

Myriad Genetics reported that Chief Operating Officer Mark Verratti had 2,055 shares of Common Stock withheld. The shares were used to cover tax obligations arising from the vesting of previously granted restricted stock units.

Was the Myriad Genetics (MYGN) COO transaction an open-market sale?

No, the transaction was not an open-market sale. The 2,055 shares of Common Stock were withheld by the company to satisfy tax withholding obligations connected to restricted stock unit vesting, rather than being sold on the market.

How many Myriad Genetics (MYGN) shares were withheld for taxes and at what price?

A total of 2,055 shares of Myriad Genetics Common Stock were withheld at $4.58 per share. This withholding satisfied tax obligations linked to the vesting of restricted stock units previously granted to Chief Operating Officer Mark Verratti.

How many Myriad Genetics (MYGN) shares does Mark Verratti hold after this filing?

After the tax-withholding disposition, Mark Verratti directly holds 630,715 shares of Myriad Genetics Common Stock. This figure reflects his position following the 2,055-share withholding used to cover tax obligations from restricted stock unit vesting.

What triggered the tax withholding of shares for Myriad Genetics (MYGN) COO?

The tax withholding was triggered by the vesting of restricted stock units previously granted to Chief Operating Officer Mark Verratti. The company withheld 2,055 shares of Common Stock to cover related tax obligations, based on the March 20, 2026 closing share price.

How was the number of withheld Myriad Genetics (MYGN) shares determined?

The number of withheld shares was determined using the closing price of Myriad Genetics Common Stock on March 20, 2026. This price was applied to calculate how many shares, totaling 2,055, were needed to satisfy Verratti’s tax withholding obligations.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Verratti Mark

(Last) (First) (Middle)

322 NORTH 2200 WEST

(Street)

SALT LAKE CITY UTAH 84116

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
MYRIAD GENETICS INC [ MYGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/22/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/22/2026		F		2,055(1)	D	$4.58	630,715	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares of Common Stock withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units previously granted to the Reporting Person. The number of shares withheld was determined based on the closing price of Issuer's Common Stock on March 20, 2026.

Remarks:

	By: Justin Hunter For: Mark Verratti	03/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)